Stock AEZS AETERNA ZENTARIS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Aeterna Zentaris Inc. Stock

Equities

AEZS

CA0079755017

Biotechnology & Medical Research

Market Closed - Toronto S.E.
Other stock markets
 03:55:03 2024-04-15 pm EDT 		5-day change 1st Jan Change
2.7 CAD -3.23% Intraday chart for Aeterna Zentaris Inc. -2.53% +5.06%
Apr. 03 North American Morning Briefing : Powell Awaited -2- DJ
Mar. 28 Ceapro Brief: Parties anticipate completing Transaction in Q2 2024, subject to obtaining all required approvals and satisfying all required conditions MT

Financials

Sales 2022 5.64M 7.78M Sales 2023 4.5M 6.2M Capitalization 9.41M 12.98M
Net income 2022 -22M -30.34M Net income 2023 -16M -22.06M EV / Sales 2022 -6.21 x
Net cash position 2022 50.43M 69.54M Net cash position 2023 33.74M 46.52M EV / Sales 2023 -5.41 x
P/E ratio 2022
-0.68 x
P/E ratio 2023
-0.57 x
Employees 12
Yield 2022 *
-
Yield 2023
-
Free-Float 96.05%
More Fundamentals * Assessed data

Chart Aeterna Zentaris Inc.

Dynamic Chart

Latest news about Aeterna Zentaris Inc.

North American Morning Briefing : Powell Awaited -2- DJ
Ceapro Brief: Parties anticipate completing Transaction in Q2 2024, subject to obtaining all required approvals and satisfying all required conditions MT
Ceapro Brief: Says Received Final Court Approval for Merger with Aeterna Zentaris MT
Aeterna Zentaris Reports Q4 Net Loss of US$5.6 Million, Provides DETECT Trial Update MT
Aeterna Zentaris Brief: Announcing Completion of Enrollment in Ongoing Pivotal DETECT-Trial for Diagnosis of Childhood-Onset Growth Hormone Deficiency MT
Aeterna Zentaris Brief: Reporting Q4 Net Loss of US$5.6 million, or $1.16 loss per common share MT
Aeterna Zentaris Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
North American Morning Briefing : Stocks Edge -2- DJ
North American Morning Briefing : Markets on Hold -2- DJ
Ceapro Brief: Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR Arrangement Agreement to Approve Merger of Equals to Create a Diversified Biopharmaceutical Co MT
Traders Search for Fresh Cues After Fed-Driven Rally as US Equity Futures Waver Pre-Bell MT
Top Premarket Gainers MT
Aeterna Zentaris and Ceapro Announce Merger of Equals to Create Diversified Biopharmaceutical Co MT
Aeterna Zentaris and Ceapro Brief: Cos Announcing Merger of Equals to Create a Diversified Biopharmaceutical Co MT
Aeterna Zentaris Inc. entered into a definitive agreement to acquire Ceapro Inc. for CAD 20 million in a merger of equals transaction. CI
More news

Latest transcript on Aeterna Zentaris Inc.

Logo Aeterna Zentaris Inc.
Aeterna Zentaris Inc. - Special Call
More transcripts

Analyst Recommendations on Aeterna Zentaris Inc.

HC Wainwright Cuts Aeterna Zentaris' Price Target to $15 From $28, Maintains Buy Rating MT
HC Wainwright Trims AEterna Zentaris Price Target to $1.50 From $2, Maintains Buy Rating MT
AETERNA ZENTARIS : HC Wainwright Starts AEterna Zentaris at Buy With $2 Price Target MT
DJ Industrial : Wall Street Futures in Red Territory Ahead of Fed Rate Decision MT
More recommendations

Press releases Aeterna Zentaris Inc.

Aeterna Zentaris Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Completion of Enrollment in Ongoing Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency AQ
Aeterna Zentaris : Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Completion of Enrollment in Ongoing Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency - Form 6-K PU
Aeterna Zentaris : Consolidated Financial Statements As of December 31, 2023 and 2022 and for the years ended December 31, 2023, 2022 and 2021 - Form 6-K PU
Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings AQ
Aeterna Zentaris Issues Letter to Shareholders and Management Proxy Circular Ahead of Special Meeting of Shareholders to Approve Merger of Equals with Ceapro AQ
More press releases

News in other languages on Aeterna Zentaris Inc.

Aeterna Zentaris Inc : 2 avril 2012 Aeterna Zentaris annonce les données sommaires de l’étude de phase 3 avec perifosine sur le cancer colorectal avancé réfractaire
Aeterna Zentaris Inc : 26 mars 2012 Aeterna Zentaris présentera des données précliniques sur les composés anticancéreux, perifosine et AEZS-136, à la prochaine rencontre de l’AACR
Aeterna Zentaris Inc : 8 mars 2012 Aeterna Zentaris : Le Michael E. DeBakey VA Medical Center lance une étude de phase 2A sur la cachexie induite par le cancer avec le composé agoniste de la ghréline, AEZS-130
Aeterna Zentaris Inc : 29 février 2012 Aeterna Zentaris fera une présentation à la Cowen and Company 32nd Annual Health Care Conference à Boston
Aeterna Zentaris Inc : 9 février 2012 22573
More news

Quotes and Performance

1 day-3.23%
1 week-2.53%
Current month-7.22%
1 month-6.57%
3 months-0.74%
6 months+3.45%
Current year+5.06%
More quotes

Highs and lows

1 week
2.69
Extreme 2.69
2.85
1 month
2.68
Extreme 2.68
3.06
Current year
2.28
Extreme 2.28
3.18
1 year
1.91
Extreme 1.91
4.48
3 years
1.91
Extreme 1.91
36.00
5 years
1.91
Extreme 1.91
147.25
10 years
1.91
Extreme 1.91
4 200.00
More quotes

Managers and Directors - Aeterna Zentaris Inc.

Managers TitleAgeSince
Klaus Wolfgang Paulini CEO
 Chief Executive Officer 60 19-10-03
Giuliano La Fratta DFI
 Director of Finance/CFO - 22-01-23
Patricia Zahn ADM
 Chief Administrative Officer - 15-09-30
Members of the board TitleAgeSince
Gilles Gagnon BRD
 Director/Board Member 70 19-12-31
Peter Edwards BRD
 Director/Board Member 62 20-05-14
Dennis Turpin BRD
 Director/Board Member - 21-05-04
More insiders

Quotes

Date Price Change Volume
24-04-15 2.7 -3.23% 1,615
24-04-12 2.79 -1.06% 384
24-04-11 2.82 -1.05% 329
24-04-10 2.85 +2.89% 118

Delayed Quote Toronto S.E., April 15, 2024 at 03:55 pm EDT

More quotes

Company Profile

Aeterna Zentaris Inc. is a Canada-based specialty biopharmaceutical company. The Company is developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products focused on areas of significant unmet medical need. The Company's lead product, macimorelin (Macrilen, Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also leveraging the clinical and compelling safety profile of macimorelin to develop it for the diagnosis of childhood-onset growth hormone deficiency (CGHD). The Company is engaged in the development of its therapeutic asset and has established a pre-clinical development pipeline to potentially address unmet medical needs across a number of indications, including neuromyelitis optica spectrum disorder (NMOSD), Parkinson's disease (PD), hypoparathyroidism and amyotrophic lateral sclerosis (ALS). Its therapeutic development pipeline includes AIM Biologicals, AEZS-150 and AEZS-130.
Sector
Biotechnology & Medical Research
Calendar
2024-05-06 - Q1 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
AETERNA ZENTARIS INC. Stock Aeterna Zentaris Inc.
+5.06% 9.85M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-0.10% 42.63B
LONZA GROUP AG Stock Lonza Group AG
+50.98% 42.32B
MODERNA, INC. Stock Moderna, Inc.
+4.43% 40.26B
CELLTRION, INC. Stock Celltrion, Inc.
-11.36% 27.27B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+5.67% 25.24B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-22.84% 18.78B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-0.20% 12.39B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+26.30% 12.24B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.91% 10.95B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. AEZS Stock